Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGRET: First-in-human Phase I study of AZD9592 in advanced solid tumors
jRCT2031230002Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of tilatamig samrotecan in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Oral Mucosal Carcinoma and 1 more (4 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 3 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
tilatamig samrotecan
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Oral Mucosal Carcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031230002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230002.